Semi-rational Design of Target-binding Small Proteins for Cancer Treatment.

[Semi-rational Design of Target-binding Small Proteins for Cancer Treatment]. Yakugaku Zasshi. 2020;140(2):159-162 Authors: Kadonosono T, Kizaka-Kondoh S Abstract Small proteins that have a high affinity for cancer cell surface markers can be promising cheap alternatives to antibodies (antibody mimetics). Various types of antibody mimetics have thus been extensively developed. We recently found that a target-binding peptide binds to its target molecule more strongly when it is structurally constrained. To apply this finding to the development of chemically synthesizable small antibody mimetics, we have established an efficient method of creating such proteins, named fluctuation-regulated affinity proteins (FLAPs). To identify desirable scaffolds, first, 13 human proteins (46-104 aa) were selected from the Protein Data Bank. Then, thirteen graft acceptor (GA) sites that efficiently immobilize the grafted peptide structure were identified from six small protein scaffolds using molecular dynamics simulation. To assess the designed antibody mimetics in vitro, human epidermal growth factor receptor 2 (HER2)-binding peptides were selected from the anti-HER2 antibody drugs trastuzumab and pertuzumab by calculating the binding energy, and these were then grafted into the GA sites of scaffolds to create 65 FLAP candidates. The FLAP candidates were expressed in bacteria as fusion proteins with Renilla luciferase (Rluc), and their relative binding affinity to HER2 ...
Source: Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan - Category: Drugs & Pharmacology Authors: Tags: Yakugaku Zasshi Source Type: research

Related Links:

Authors: Gomes I, de Almeida BP, Dâmaso S, Mansinho A, Correia I, Henriques S, Cruz-Duarte R, Vilhais G, Félix P, Alves P, Corredeira P, Barbosa-Morais NL, Costa L, Casimiro S Abstract The role of RANKL-RANK pathway in progesterone-driven mammary carcinogenesis and triple negative breast cancer tumorigenesis has been well characterized. However, and despite evidences of the existence of RANK-positive hormone receptor (HR)-positive breast tumors, the implication of RANK expression in HR-positive breast cancers has not been addressed before. Here, we report that RANK pathway affects the expression of cel...
Source: Oncotarget - Category: Cancer & Oncology Tags: Oncotarget Source Type: research
British Journal of Cancer, Published online: 03 June 2020; doi:10.1038/s41416-020-0909-4Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes—a Hellenic Cooperative Oncology Group (HeCOG) Trial
Source: British Journal of Cancer - Category: Cancer & Oncology Authors: Source Type: research
ConclusionOur pooled analysis supports the use of SP in the first-line setting for patients with HER2-negative advanced or recurrent GC with a recurrence-free interval of  ≥ 6 months.Clinical trial registrationThe HERBIS-2 trial was registered with UMIN-CTR as UMIN000006105.
Source: International Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
Cancers, Vol. 12, Pages 1453: DSCAM-AS1-Driven Proliferation of Breast Cancer Cells Involves Regulation of Alternative Exon Splicing and 3′-End Usage Cancers doi: 10.3390/cancers12061453 Authors: Jamal Elhasnaoui Valentina Miano Giulio Ferrero Elena Doria Antonette E. Leon Aline S. C. Fabricio Laura Annaratone Isabella Castellano Anna Sapino Michele De Bortoli DSCAM-AS1 is a cancer-related long noncoding RNA with higher expression levels in Luminal A, B, and HER2-positive Breast Carcinoma (BC), where its expression is strongly dependent on Estrogen Receptor Alpha (ERα). DSCAM-AS1 e...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractPrevious studies reported heterogeneous associations between obesity and reproductive-related breast cancer risk factors and breast cancer intrinsic subtypes; however, few studies have been conducted in Asian populations. Here, we aimed to examine whether risks associated with established breast cancer risk factors varied by breast cancer subtypes in Chinese women. We conducted a hospital-based case-control study in Hong Kong, including a total of 2169 Chinese women. Unconditional polytomous logistic regression models were used to calculate adjusted odds ratios (AORs) and 95% confidence intervals(95%CIs) to estimat...
Source: Hormones and Cancer - Category: Cancer & Oncology Source Type: research
ndi Francesco Massari Urothelial carcinoma (UC) is a frequent cause of cancer-related deaths worldwide. Metastatic UC has been historically associated with poor prognosis, with a median overall survival of approximately 15 months and a 5-year survival rate of 18%. Although platinum-based chemotherapy remains the mainstay of medical treatment for patients with metastatic UC, chemotherapy clinical trials produced modest benefit with short-lived, disappointing responses. In recent years, the better understanding of the role of immune system in cancer control has led to the development and approval of several immunothera...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Durable responses seen in phase 2 trial of trastuzumab deruxtecan in patients with heavily pretreated HER2-positive colorectal cancer suggests that HER2 testing become standard of care, argues expert.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Publication date: June 2020Source: European Journal of Surgical Oncology, Volume 46, Issue 6Author(s): Amber Shivarajan, Hiba Fatayer, Nicholas Hobbs, Sami Titi, Nabila Nasir
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
In HER2-positive breast cancer patients with brain metastases treated with trastuzumab and capecitabine, tucatinib increased median overall survival from 12 months to 18.1 months in a phase 2 trial.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Contributors : Liu Yuan ; Zhu ZhouSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensA large-panel gene expression analysis was conducted to identify biomarkers associated with the effectiveness of adding palbociclib to letrozoleCyclin-dependent kinase 4/6 (CDK4/6) inhibitors have demonstrated significant activity in estrogen receptor-positive/human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer. Further biomarkers to refine the population beyond ER+/HER2- that benefits remain to be identified. We performed a comprehensive biomarker analysis using patient ...
Source: GEO: Gene Expression Omnibus - Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research
More News: Cancer | Cancer & Oncology | Chemistry | Drugs & Pharmacology | HER2 | Herceptin | Japan Health